Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries

被引:105
作者
Chalkidou, Kalipso [1 ]
Marquez, Patricio [2 ]
Dhillon, Preet K. [3 ]
Teerawattananon, Yot [4 ]
Anothaisintawee, Thunyarat [5 ]
Gadelha, Carlos Augusto Grabois [6 ,7 ]
Sullivan, Richard [8 ,9 ]
机构
[1] NICE Int, London SW1 2BU, England
[2] World Bank, Accra, Ghana
[3] Publ Hlth Fdn India, South Asia Network Chron Dis, New Delhi, India
[4] Minist Publ Hlth, Hlth Intervent & Technol Assessment Program, Nonthaburi, Thailand
[5] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Family Med, Bangkok 10400, Thailand
[6] Fundacao Oswaldo Cruz, Minist Hlth, Brasilia, DF, Brazil
[7] Fundacao Oswaldo Cruz, Natl Sch Publ Hlth, Brasilia, DF, Brazil
[8] Kings Coll London, Kings Hlth Partners Canc Ctr, London WC2R 2LS, England
[9] Kings Coll London, Inst Canc Policy, London WC2R 2LS, England
关键词
OUT-OF-POCKET; UNITED-STATES; CERVICAL-CANCER; EUROPEAN-UNION; BURDEN; HEALTH; MORTALITY; GUIDELINES; DRUGS; EXPENDITURE;
D O I
10.1016/S1470-2045(13)70547-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Evidence-informed frameworks for cost-effective cancer prevention and management are essential for delivering equitable outcomes and tackling the growing burden of cancer in all resource settings. Evidence can help address the demand side pressures (ie, pressures exerted by people who need care) faced by economies with high, middle, and low incomes, particularly in the context of transitioning towards (or sustaining) universal health-care coverage. Strong systems, as opposed to technology-based solutions, can drive the development and implementation of evidence-informed frameworks for prevention and management of cancer in an equitable and affordable way. For this to succeed, different stakeholders-including national governments, global donors, the commercial sector, and service delivery institutions-must work together to address the growing burden of cancer across economies of low, middle, and high income.
引用
收藏
页码:E119 / E131
页数:13
相关论文
共 86 条
  • [1] The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
    Abboud, Camille
    Berman, Ellin
    Cohen, Adam
    Cortes, Jorge
    DeAngelo, Daniel
    Deininger, Michael
    Devine, Steven
    Druker, Brian
    Fathi, Amir
    Jabbour, Elias
    Jagasia, Madan
    Kantarjian, Hagop
    Khoury, Jean
    Laneuville, Pierre
    Larson, Richard
    Lipton, Jeffrey
    Moore, Joseph O.
    Mughal, Tariq
    O'Brien, Susan
    Pinilla-Ibarz, Javier
    Quintas-Cardama, Alfonso
    Radich, Jerald
    Reddy, Vishnu
    Schiffer, Charles
    Shah, Neil
    Shami, Paul
    Silver, Richard T.
    Snyder, David
    Stone, Richard
    Talpaz, Moshe
    Tefferi, Ayalew
    Van Etten, Richard A.
    Wetzler, Meir
    Abruzzese, Elisabetta
    Apperley, Jane
    Breccia, Massimo
    Byrne, Jenny
    Cervantes, Francisco
    Chelysheva, Ekaterina
    Clark, R. E.
    de Lavallade, Hugues
    Dyagil, Iryna
    Gambacorti-Passerini, Carlo
    Goldman, John
    Haznedaroglu, Ibrahim
    Hjorth-Hansen, Henrik
    Holyoake, Tessa
    Huntly, Brian
    le Coutre, Philipp
    Lomaia, Elza
    [J]. BLOOD, 2013, 121 (22) : 4439 - 4442
  • [2] Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states
    Ades, F.
    Senterre, C.
    de Azambuja, E.
    Sullivan, R.
    Popescu, R.
    Parent, F.
    Piccart, M.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (11) : 2897 - 2902
  • [3] Making progress against cancer in Europe in 2008
    Albreht, Tit
    McKee, Martin
    Alexe, Delia-Marina
    Coleman, Michel P.
    Martin-Moreno, Jose M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2008, 44 (10) : 1451 - 1456
  • [4] All-Party Parliamentary Group on Global Health, 2013, IMPR HLTH HOM ABR OV
  • [5] Almeida Ribeiro A. S. M, 2012, POLITICAS SISTEMA SA, P143
  • [6] Has the time come for metronomics in low-income and middle-income countries?
    Andre, Nicolas
    Banavali, Shripad
    Snihur, Yuliya
    Pasquier, Eddy
    [J]. LANCET ONCOLOGY, 2013, 14 (06) : E239 - E248
  • [7] [Anonymous], 2012, World Development Report
  • [8] [Anonymous], SKIN CANC PREV INF R
  • [9] [Anonymous], 2010, MMWR-MORBID MORTAL W, V60, P1315
  • [10] [Anonymous], 2011, CLIN PRACTICE GUIDEL